Patents by Inventor Alison Turner

Alison Turner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST KLK5
    Publication number: 20230075753
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • ANTIBODIES AGAINST KLK5
    Publication number: 20230070261
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 11518803
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: December 6, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20200407436
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosis
    Patent number: 10766956
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • ANTAGONIST ANTIBODIES THAT BIND TO HUMAN TGFB1, TGFB2 AND TO TGFB3 AND THEIR USE FOR THE TREATMENT OF LUNG FIBROSIS
    Publication number: 20190330321
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 31, 2019
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • Tri- and tetra-valent monospecific antigen-binding proteins
    Patent number: 6511663
    Abstract: The invention provides a tri- or tetra-valent monospecific antigen-binding protein comprising three or four Fab fragments bound to each other covalently by a connecting structure, which protein is not a natural immunoglobuline. Further provided are novel connecting structures for use in assembling the proteins of the invention and means for attaching a labeling or effector group thereto. The proteins of the invention are useful, for example, in the treatment and diagnosis of cancer.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: January 28, 2003
    Assignee: Celltech R&D Limited
    Inventors: David John King, Alison Turner, Nigel Robert Arnold Beeley, Thomas Andrew Millican
  • Polymer compositions containing a bisazomethine pigment
    Patent number: 4038241
    Abstract: Polymer compositions containing as a pigment a compound having the formula: ##STR1## in the pigmentary form in which it has an orange-red color and has an X chromaticity co-ordinate of from 0.59 to 0.63 and a Y chromaticity of from 0.33 to 0.36, each as hereinbefore defined.
    Type: Grant
    Filed: November 22, 1974
    Date of Patent: July 26, 1977
    Assignee: Ciba-Geigy Corporation
    Inventors: Eric Richard Inman, James McGeachie McCrae, Christopher Midcalf, Alison Turner